Español
India
Italiano
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Zepbound
Ben & Jerry's Co-Founders Not Worried About Ozempic's Impact On Ice Cream Business: Here's Why
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
'Not Just A Weight Loss Story:' Eli Lilly CEO Thinks It's Possible To Meet BofA's $60B Revenue Projection From New Drug Launches
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
'Not Just A Weight Loss Story:' Eli Lilly CEO Thinks It's Possible To Meet BofA's $60B Revenue Projection From New Drug Launches
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy
Costco Long Known For Rotisserie Chicken And Hot Dogs Counters Junk Food With Weight Loss Plan To Help You Shed Those Extras
Zepbound Recent News
Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions
Eli Lilly stock is up 32% so far in 2024 and has risen 318% over three years.
Top 7 Biotech Stock Winners As Weight Loss Drug Battle Escalates: Goldman Sachs Names Best Picks
Goldman Sachs analysts identified a substantial opportunity in the manufacturing sector for new obesity therapeutics, as demand for these treatments escalates.
Eli Lilly Soars On Diabetes And Obesity Drug Boom, Projects 20% Revenue Increase In 2024
This surge is attributed to the popularity of Lilly's new diabetes drug, Mounjaro, and its anti-obesity medication, Zepbound.
Tesla's Market Cap Dips Below Eli Lilly Following Q4 Revenue Miss
Eli Lilly Launches Website To Help Patients With Home Delivery Options For Weight Loss Medicines
Eli Lilly announced a new website allowing patients to get a weight loss drug prescription through a telehealth provider, with disease management resources, home delivery of medicines.